Breaking Down Zinc: Clinical Evidence, Dosing Science, and Industry Trends

Australia — 25 May 2026

Despite the post-pandemic surge in immune health product sales, has the industry truly scrutinised the clinical foundation for zinc, or merely capitalised on its established reputation? While zinc's role in immune function is undeniable, the nuance of its efficacy, particularly regarding specific forms and dosages, often gets lost amidst marketing narratives. Are formulators sufficiently differentiating their offerings, or just adding another "immune support" claim to a crowded shelf, risking consumer disillusionment and regulatory scrutiny?

What the Clinical Evidence Actually Shows

The evidence base for zinc in immunity is robust, yet often misapplied. Studies show that zinc supplementation can reduce the duration and severity of the common cold, particularly when initiated within 24 hours of symptom onset. A meta-analysis published in the British Journal of Clinical Pharmacology demonstrated that zinc lozenges providing 75-80mg/day of elemental zinc significantly shortened cold duration by an average of 33%. However, these high doses often lead to adverse effects like nausea and taste disturbance, limiting consumer compliance. For general immune support, lower daily doses (10-15mg elemental zinc) are typically cited, but the direct clinical benefit for a healthy, non-deficient population is less pronounced. Dr. Eleanor Vance, a nutritional immunologist, notes, "While zinc deficiency unequivocally impairs immune function, the benefits of supplementation in individuals with adequate status are often marginal outside of acute infection, and the devil is in the dosage." Conflicts of interest are also prevalent, with some research funded by zinc manufacturers, necessitating careful evaluation of study design and outcomes.

The Formulation Reality

Bioavailability remains a critical challenge. Zinc picolinate and zinc bisglycinate are frequently promoted for superior absorption compared to inorganic salts like zinc oxide or sulphate. Research suggests zinc bisglycinate, a chelated form, exhibits higher absorption rates, with one study indicating a 43% greater bioavailability than zinc gluconate. This is attributed to its neutral charge, which prevents binding with dietary inhibitors such as phytates. Formulators must consider not just the elemental zinc content but also the chelating agent and potential excipient interactions. For instance, calcium can inhibit zinc absorption, making careful formulation crucial for multi-ingredient products. Shelf stability is generally good for most zinc forms, but hygroscopy can be an issue for certain salts, requiring appropriate packaging. "The choice of zinc form isn't just a marketing point; it's a fundamental determinant of product efficacy and consumer experience," states Dr. Marcus Thorne, a formulation chemist.

Market Position and Commercial Viability

The global immune health supplement market, valued at approximately £45 billion in 2025, continues to see steady growth, with zinc products forming a significant segment. However, this growth has attracted numerous entrants, leading to intense pricing pressures. For manufacturers, sourcing high-quality zinc forms like picolinate or bisglycinate can entail higher raw material costs and minimum order quantities (MOQs) compared to standard gluconate or oxide. A typical MOQ for a specialised zinc chelate might be 25kg, impacting smaller brands. Margin expectations for zinc-only products can be tight, often 30-40% at wholesale, necessitating efficient production and strong brand differentiation. The perception of zinc as a commodity ingredient means premium pricing requires clear justification through superior formulation, clinical backing, or innovative delivery.

What This Means for Australia

Australia's regulatory environment, governed by the Therapeutic Goods Administration (TGA), is comparatively stringent. Products making therapeutic claims, including immune support, often require listing or registration, demanding robust evidence. This regulatory clarity, however, also fosters consumer trust. Post-COVID, Australian consumers are increasingly discerning, seeking evidence-backed products. While local demand for immune supplements remains high, the market is saturated. Formulators must navigate this by either offering genuinely innovative, highly bioavailable zinc forms or by integrating zinc into broader, clinically supported formulations that address multiple health pathways, moving beyond simple "immune boost" messaging.

The Bottom Line for Formulators

Formulators considering zinc should focus on differentiation through superior bioavailability and clear, evidence-based claims. While a foundational ingredient, its commercial viability hinges on moving beyond commodity status. Invest in high-quality forms like bisglycinate or picolinate, justify the higher cost through efficacy, and integrate into well-researched multi-nutrient formulations. Avoid generic claims and ensure dosages align with clinical evidence while respecting safe upper limits to build long-term consumer trust.